

Hepatic Insufficiency

What happens to a medicine (entrectinib) when given to people with unhealthy livers

A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function

Trial Status
Completed

Trial Runs In
3 Countries

Trial Identifier
NCT04226833 2019-003065-17
GP41174

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study an approved medicine called, “entrectinib”, for the treatment of patients with certain types of cancers. This study was done to find out what happens to entrectinib in the body when it is given to people who have an unhealthy liver. Researchers also wanted to know if there was a relationship between the amount of entrectinib available in the body and the health status and function of the liver. Thirty-eight people took part in this study at three study centers in three countries. Some people had a healthy liver while others had an unhealthy liver.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT04226833 2019-003065-17 GP41174
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 75 Years

Healthy Volunteers
Accepts Healthy Volunteers
